Together with clinicians, Direct Genomics is making genomics an affordable part of everyday patient care. The company’s GenoCare instrument is the first single molecule sequencing system for clinical use. That simplifies sequencing by directly reading individual DNA and RNA molecule information from customer’s blood or tissue samples, delivering significant improvements in cost and speed. Established in 2012, Direct Genomics is headquartered in Shenzhen, China and backed by institutional and private investors.
Direct Genomics is developing a third generation technology of genome sequencing that has a huge market potential in noninvasive detection, disease diagnosis, and personalized treatment. Our vision is to become a leading player in the upstream sector of the sequencing industry with the best solutions for quality, quantity and affordability of sequencing products. Direct Genomics is poised to create a sustainable and profitable company by continuous innovation and strong partnerships with industry leaders.